Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Oligonucleotide therapeutics in cancer.

Wan J, Bauman JA, Graziewicz MA, Sazani P, Kole R.

Cancer Treat Res. 2013;158:213-33. doi: 10.1007/978-3-642-31659-3_9.

PMID:
24222360
2.

[Recent progress and prospect in oligonucleotide therapeutics].

Yoshioka K, Kuwahara H, Nishina K, Nagata T, Yokota T.

Nihon Rinsho. 2015 Jun;73(6):1057-65. Review. Japanese.

PMID:
26065142
3.

Splice-switching antisense oligonucleotides as therapeutic drugs.

Havens MA, Hastings ML.

Nucleic Acids Res. 2016 Aug 19;44(14):6549-63. doi: 10.1093/nar/gkw533. Epub 2016 Jun 10. Review.

4.

Antisense and/or immunostimulatory oligonucleotide therapeutics.

Agrawal S, Kandimalla ER.

Curr Cancer Drug Targets. 2001 Nov;1(3):197-209. Review.

PMID:
12188879
5.

Antisense oligonucleotides as therapeutics for malignant diseases.

Ho PT, Parkinson DR.

Semin Oncol. 1997 Apr;24(2):187-202. Review.

PMID:
9129689
6.

Liver as a target for oligonucleotide therapeutics.

Sehgal A, Vaishnaw A, Fitzgerald K.

J Hepatol. 2013 Dec;59(6):1354-9. doi: 10.1016/j.jhep.2013.05.045. Epub 2013 Jun 12.

7.
8.

Modulation of RNA splicing as a potential treatment for cancer.

Bauman JA, Kole R.

Bioeng Bugs. 2011 May-Jun;2(3):125-8. Epub 2011 May 1.

9.

Antisense oligonucleotides: the state of the art.

Aboul-Fadl T.

Curr Med Chem. 2005;12(19):2193-214. Review.

PMID:
16178780
10.
11.

Antisense oligonucleotides.

Kashihara N, Maeshima Y, Makino H.

Exp Nephrol. 1998 Jan-Feb;6(1):84-8. Review.

PMID:
9523178
12.

Modification of alternative splicing by antisense oligonucleotides as a potential chemotherapy for cancer and other diseases.

Mercatante DR, Sazani P, Kole R.

Curr Cancer Drug Targets. 2001 Nov;1(3):211-30. Review.

PMID:
12188880
13.

Antisense-mediated exon skipping to shift alternative splicing to treat cancer.

Wan J.

Methods Mol Biol. 2012;867:201-8. doi: 10.1007/978-1-61779-767-5_13.

PMID:
22454063
14.

Anti-tumor activity of splice-switching oligonucleotides.

Bauman JA, Li SD, Yang A, Huang L, Kole R.

Nucleic Acids Res. 2010 Dec;38(22):8348-56. doi: 10.1093/nar/gkq731. Epub 2010 Aug 18.

15.

Antisense-mediated redirection of mRNA splicing.

Vacek M, Sazani P, Kole R.

Cell Mol Life Sci. 2003 May;60(5):825-33. Review.

PMID:
12827272
16.

Progress toward therapy with antisense-mediated splicing modulation.

Du L, Gatti RA.

Curr Opin Mol Ther. 2009 Apr;11(2):116-23. Review.

17.

Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice.

Roberts J, Palma E, Sazani P, Ørum H, Cho M, Kole R.

Mol Ther. 2006 Oct;14(4):471-5. Epub 2006 Jul 18.

18.

Antisense therapy in oncology: new hope for an old idea?

Tamm I, Dörken B, Hartmann G.

Lancet. 2001 Aug 11;358(9280):489-97. Review.

PMID:
11513935
19.

Reprogramming alternative pre-messenger RNA splicing through the use of protein-binding antisense oligonucleotides.

Villemaire J, Dion I, Elela SA, Chabot B.

J Biol Chem. 2003 Dec 12;278(50):50031-9. Epub 2003 Sep 30.

20.

Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms.

Chiang MY, Chan H, Zounes MA, Freier SM, Lima WF, Bennett CF.

J Biol Chem. 1991 Sep 25;266(27):18162-71.

Supplemental Content

Support Center